BriefMD

Specialties / Nephrology

New Nephrology research.

The strongest recent Nephrology papers on PubMed, ranked by study design, topic and journal, with the same summaries subscribers get.

  1. randomized trial, 96 patients

    Effects of E-Coach-Based Chronic Disease Management on Self-Management, Quality of Life, and Mental Health in Maintenance Hemodialysis Patients

    Zhang Y, Xing J, Wang GX, et al. J Vis Exp. Oct 2026.

    Findings
    In hemodialysis patients, self-management scores improved significantly with E-Coach compared with usual care, showing a mean difference of +11.6 (95%CI: 9.7 to 13.6; p < 0.001 by Bonferroni correction). The between-group difference in change was +13.3 (95%CI: 9.9 to 16.5).
    Bottom line
    Adding an E-Coach intervention effectively boosts self-management behavior scores in maintenance hemodialysis patients.

    PubMed, PMID 42921780

  2. randomized trial, 66 patients

    PlasmaLyte, Lactated Ringer's, or Normal Saline resuscitation in acute pancreatitis: a single-center, pragmatic, cluster-randomized trial

    Sin SH, Kim HK, Choi HH, et al. BMC Gastroenterol. Jul 2026.

    Findings
    Among 66 acute pancreatitis patients, SIRS prevalence fell to 4.8% with PlasmaLyte (80% reduction), 12.5% with Lactated Ringer’s (57.1% reduction) and 9.5% with Normal Saline (50% reduction).
    Bottom line
    Balanced crystalloids lowered SIRS more than saline, though differences were not statistically significant.

    PubMed, PMID 42897479

  3. phase iii trial, 485 patients

    Ravulizumab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial

    Barratt J, Farag YMK, Rice K, et al. N Engl J Med. Oct 2026.

    Findings
    In 485 randomized patients, ravulizumab reduced the 24‑hour urinary protein‑to‑creatinine ratio by -46.6% versus -5.6% with placebo, a 43.4% lower adjusted ratio (P<0.001). Adverse events occurred in 69.5% of ravulizumab‑treated patients and 75.8% of placebo patients.
    Bottom line
    Ravulizumab achieved a -46.6% reduction in protein‑to‑creatinine ratio, with adverse events in 69.5% versus 75.8% on placebo.

    PubMed, PMID 42912700

Summaries are written by AI from PubMed abstracts, for keeping up with the literature. Check the source before it changes care. Editorial policy · Medical disclaimer

Get Nephrology research every morning.

Free. Choose your Nephrology topics after you subscribe.